Progress of research on molecular targeted therapies for colorectal cancer

Progress of research on molecular targeted therapies for colorectal cancer

Colorectal cancer (CRC) is one of the most common malignancies, accounting for approximately 10% of global cancer incidence and mortality. Approximately 20% of patients with CRC present metastatic disease (mCRC) at the time of diagnosis. Moreover, up to 50% of patients with localized disease eventua...

Full description

Bibliographic Details
Main Authors: Shilin Huang, Jiazhou Ye, Xing Gao, Xi Huang, Julu Huang, Lu Lu, Cheng Lu, Yongqiang Li, Min Luo, Mingzhi Xie, Yan Lin, Rong Liang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
colorectal cancer
EGFR
HER2
BRAF
anti-angiogenic
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1160949/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1160949/full

Similar Items